PureTech Health (PRTC) Long-Term Investments (2019 - 2024)
PureTech Health (PRTC) reported Long-Term Investments of $2.4 million for Q4 2024, down 73.79% on a QoQ basis from $9.1 million in Q4 2022.
PureTech Health (PRTC) has 3 years of Long-Term Investments data on file, last reported at $2.4 million in Q4 2024.
- Quarterly Long-Term Investments changed N/A year-over-year to $2.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $2.4 million (changed N/A YoY) and the FY2024 annual result came in at $2.4 million, changed N/A from the prior year.
- Long-Term Investments eased to $2.4 million in Q4 2024 per PRTC's latest filing, from $9.1 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $9.1 million in Q4 2022 and bottomed at $2.4 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 9.79 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 22.17 Mn |
| 10 | PureTech Health | 86.36 Mn | -190.94 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.40 Mn |
| Dec 31, 2022 | 9.15 Mn |
| Dec 31, 2019 | 10.64 Mn |